Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences


Crinetics' management will participate in three upcoming investor conferences: the Evercore 7th Annual HealthConx Conference on December 3rd, the Citi Global Healthcare Conference on December 4th, and the Piper Sandler 36th Annual Healthcare Conference on December 5th.

Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting


Crinetics to showcase pipeline advancements with neuroendocrine tumor candidates at the 2024 NANETS Annual Meeting.

Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update


Crinetics Pharmaceuticals reported third quarter 2024 financial and provided a business update on clinical progress.

Crinetics Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 99,500 shares of its common stock to eleven new non-executive employees.

Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024


Crinetics Pharmaceuticals announced that it will report second quarter 2024 financial results on Tuesday, November 12, after the close of the U.S. financial markets.